Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of the study is to monitor the general functional changes among patients with schizophrenia, treated with atypical antipsychotics dosed once daily for a period of 6 months.The primary study objective is to compare general functioning of patients with schizophrenia treated with Seroquel SR between baseline and the last study visit. The secondary study objectives are to compare general functioning of patients with schizophrenia treated with other atypical antipsychotic medicinal products administered once daily between baseline and the last study visit, monitoring of other indicators of clinical improvement, evaluation of patient compliance and assessment of occurrence of adverse effects
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 1 | Seroquel SR: Patients whose symptoms are controlled with Seroquel SR and started with the therapy up to 1 month before the inclusion | ||
| 2 | Atypical antipsychotics: Patients whose symptoms are controlled with atypical antipsychotic in once daily formulation (excluding Seroquel SR) and started with the therapy up to 1 month before the inclusion |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| To compare improvement in global assessment of functioning (using the GAF scale) between the baseline and the final study visit in the Seroquel SR-treated group. | three times: 0, 12 and 24 weeks after inclusion |
| Measure | Description | Time Frame |
|---|---|---|
| To assess improvement in global assessment of functioning (using the GAF scale) between the baseline and the final study visit in the group of patients treated with other atypical antipsychotics | three times: 0, 12 and 24 weeks after inclusion |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
patients visiting psychiatrist's practice
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Peter Pregelj, MD, PhD | Psihiatricna klinika Ljubljana, Studenec 48, 1260 Ljubljana | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Research Site | Begunje na Gorenjskem | Slovenia | ||||
| Research Site |
Not provided
| ID | Term |
|---|---|
| D012559 | Schizophrenia |
| ID | Term |
|---|---|
| D019967 | Schizophrenia Spectrum and Other Psychotic Disorders |
| D001523 | Mental Disorders |
Not provided
Not provided
Not provided
Not provided
Not provided
| Brezovica pri Ljubljani |
| Slovenia |
| Research Site | Brežice | Slovenia |
| Research Site | Idrija | Slovenia |
| Research Site | Koper | Slovenia |
| Research Site | Ljubljana | Slovenia |
| Research Site | Maribor | Slovenia |
| Research Site | Nova Gorica | Slovenia |
| Research Site | Novo Mesto | Slovenia |
| Research Site | Ormoz | Slovenia |
| Research Site | Postojna | Slovenia |
| Research Site | Radenci | Slovenia |
| Research Site | Sežana | Slovenia |
| Research Site | Vojnik | Slovenia |